[{"id":"7d668ceb-425e-4625-a077-dffc5f34f447","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005403","created_at":"2021-08-13T12:53:39.013Z","updated_at":"2024-07-02T16:34:36.863Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab","source_id_and_acronym":"NCT05005403","lead_sponsor":"AbbVie","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • budigalimab (ABBV-181) • ABBV-514"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 05/04/2026","primary_completion_date":" 05/04/2026","study_txt":" Completion: 05/04/2026","study_completion_date":" 05/04/2026","last_update_posted":"2024-06-10"}]